Nab-Paclitaxel Plus Durvalumab as Second/Third-Line Treatment of Advanced NSCLC
Research led by Ramaswamy Govindan, MD, of Washington University Medical School, St. Louis, found that the combination of nab-paclitaxel and durvalumab produced antitumor activity and manageable toxicity as a second/third-line treatment of patients with advanced non–small cell lung cancer (NSCLC). These results from the multiarm ABOUND.2L+ trial were presented at the 2017 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (Abstract MA 10.02) in Yokohama, Japan.
A total of 79 patients with advanced NSCLC (70% had nonsquamous disease) were assigned to receive nab-paclitaxel plus durvalumab as a later-line therapy. Of those enrolled, 11% had received prior immune checkpoint inhibitors. Immunotherapy, including platinum-doublet combination therapy, was allowed as a prior line of treatment.
Median progression-free survival was 4.5 months. Median progression-free survival was longer in those with squamous disease than in those with nonsquamous disease (5.9 vs. 4.2 months). The overall response rate was 27%. Grade 3 and 4 adverse events that were reported in over 5% of patients included neutropenia, dyspnea, and peripheral neuropathy and anemia.